Anoro Ellipta, a combination medication containing umeclidinium 62.5 mcg and vilanterol 25 mcg, is prescribed for the long-term, once-daily maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]. It is not indicated for the relief of acute bronchospasm or for asthma [1].
What is Anoro Ellipta used for?
Anoro Ellipta is designed to improve lung function in adults with COPD by helping to keep the airways open [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of acetylcholine, a substance that causes airway muscles to constrict. Vilanterol is a long-acting beta2-adrenergic agonist ( a LABA) that relaxes airway muscles. Together, these components provide a dual mechanism to ease breathing [1].
How is Anoro Ellipta administered?
Anoro Ellipta is delivered via an inhaler device called Ellipta. Patients inhale one inhalation once daily. It is crucial to use the medication as prescribed and not to use it for sudden breathing problems [1].
When does patent exclusivity for Anoro Ellipta expire?
Patent information for Anoro Ellipta can be complex and may involve multiple patents covering different aspects of the drug, its formulation, and its use. DrugPatentWatch.com tracks these patents and their expiry dates. Generally, patents provide a period of market exclusivity. For specific details on Anoro Ellipta's patent status and projected expiry dates, DrugPatentWatch.com is a valuable resource [2].
What are the potential side effects of Anoro Ellipta?
Common side effects of Anoro Ellipta may include nasopharyngitis (common cold symptoms), headache, increased blood pressure, and muscle spasms [1]. More serious side effects can occur, such as paradoxical bronchospasm (sudden worsening of breathing), heart problems (like irregular heartbeat), urinary retention, and eye problems (like glaucoma) [1]. Patients with a history of heart disease or urinary retention should discuss these risks with their doctor [1].
Are there alternatives to Anoro Ellipta for COPD treatment?
Several other medications are available for COPD management, including other LAMAs, LABAs, inhaled corticosteroids (ICS), and combination inhalers. The choice of treatment depends on individual patient needs, disease severity, and response to therapy [1]. Examples of other LAMA/LABA combinations and single-agent therapies exist, as well as treatments that include ICS [3].
How does Anoro Ellipta compare to other COPD inhalers?
Anoro Ellipta is a LAMA/LABA combination, which is one class of maintenance inhalers for COPD. Other inhalers might contain different combinations, such as ICS/LABA or ICS/LAMA/LABA. The effectiveness and side effect profiles can differ between these classes and specific medications. Clinical guidelines often recommend LAMA/LABA combinations for symptomatic COPD patients who remain breathless despite initial treatment [3].
What regulatory approvals does Anoro Ellipta have?
Anoro Ellipta has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of COPD [1]. These approvals are based on clinical trial data demonstrating the drug's safety and efficacy [1].
What clinical trial data supports Anoro Ellipta's use?
The approval of Anoro Ellipta was based on results from large-scale clinical trials that evaluated its efficacy in improving lung function and reducing exacerbations in COPD patients. Studies like the Protocol UMC-LL-3007 (oplus) and Protocol UMC-LL-3009 (inspire) demonstrated significant improvements in lung function compared to placebo and comparator treatments [1].
What are the costs associated with Anoro Ellipta?
The cost of Anoro Ellipta can vary depending on insurance coverage, pharmacy pricing, and location. Patients may inquire about patient assistance programs or co-pay cards offered by the manufacturer to help manage out-of-pocket expenses [4].
---
Sources:
[1] https://www.anoroe.com/
[2] https://www.drugpatentwatch.com/
[3] https://goldcopd.org/wp-content/uploads/2024/03/GOLD-Report-2024-MAR6.pdf
[4] https://www.gsksupplier.com/